Clinical studies recruiting near Baoding

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

This Study is a FIH Study Which is Required to Understand the PK Characteristics, MTD, RP2D and Safety Profile.
Phase 1 · Affiliated Hospital of Hebei University · Nanjing RegeneCore Biotech Co., Ltd. · NCT06756451 A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
Phase 3 · Local Institution - 0181 · Bristol-Myers Squibb · NCT06929273 A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic
Phase 3 · Research Site · AstraZeneca · NCT06868277 Timing of Anticoagulation After Emergency Endovascular Therapy for Acute Ischemic Stroke With Atrial Fibrillation
NA · Baoding Sixth Hospital · Capital Medical University · NCT07139301 JS207 Combination Therapy in Triple-negative Breast Cancer
Phase 2 · Affiliated Hospital of Hebei University · Shanghai Junshi Bioscience Co., Ltd. · NCT07045311 A Study of Lianxiaxiaopi Granules in the Treatment of Postprandial Distress Syndrome
Phase 3 · Baoding No. 1 Hospital of Traditional Chinese Medicine · Tasly Pharmaceutical Group Co., Ltd · NCT06696261 A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel
Phase 3 · Affiliated Hospital of Hebei University /ID# 239586 · AbbVie · NCT04928846 Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke (SHINY)
Phase 3 · Baoding Xushui District People's Hospital · Beijing Tiantan Hospital · NCT06157502 A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor
Phase 1/Phase 2 · Affiliated Hospital of Hebei University / School of Clinical · Huabo Biopharm Co., Ltd. · NCT06758557 An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Phase 3 · Research Site · AstraZeneca · NCT05952557 Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure
Phase 1/Phase 2 · Affiliated Hospital of Hebei University · Peking University Cancer Hospital & Institute · NCT07087223 A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
Phase 3 · Baoding NO.1 Central Hospital · Hutchmed · NCT07409428 A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Featur
Phase 3 · Local Institution - 0193 · Bristol-Myers Squibb · NCT07140913 A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With
Phase 3 · Affiliated Hospital of Hebei University · Hoffmann-La Roche · NCT05894239 Pirfenidone Capsules in the Treatment of Radiation-induced Lung Injury With or Without Immune Pneumonia
Phase 2/Phase 3 · Hebei University Affiliated Hospital · Beijing Continent Pharmaceutical Co, Ltd. · NCT07388680 RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Smal
Phase 3 · Affiliated Hospital of Hebei University · RemeGen Co., Ltd. · NCT07416474 A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Signif
Phase 2/Phase 3 · Affiliated Hospital of Hebei University · Pfizer · NCT06989437 A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
Phase 1/Phase 2 · Affiliated Hospital of Hebei University · DualityBio Inc. · NCT05150691 Timing of Anticoagulation After Emergency Endovascular Therapy for Acute Ischemic Stroke With Atrial Fibrillation 2
NA · Baoding Sixth Hospital · Capital Medical University · NCT07139314 A Study of BPI-460372 in Advanced Solid Tumor Patients
Phase 1 · Affiliated Hospital of Hebei University · Betta Pharmaceuticals Co., Ltd. · NCT05789602 A Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune Thrombocytopenia
Phase 3 · Affiliated Hospital of Hebei University / School of Clinical · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · NCT06900920 Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for L
Phase 2/Phase 3 · Affiliated Hospital of Hebei University · BioNTech SE · NCT06712316 Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus
Phase 2 · Affiliated Hospital of HeBei University · Beijing InnoCare Pharma Tech Co., Ltd. · NCT05688696 Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated S
Phase 3 · Affiliated Hospital of Hebei University · BioNTech SE · NCT06712355 A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doub
Phase 3 · Research Site · AstraZeneca · NCT06417814 Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis
Phase 1/Phase 2 · Affiliated Hospital of Hebei University · Shanghai Chia Tai Tianqing Pharmaceutical Technology Develop · NCT07266116 A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
Phase 3 · Research Site · AstraZeneca · NCT05774951 First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma
Phase 1 · Affiliated Hospital of Hebei University · EpimAb Biotherapeutics (Suzhou)Co., Ltd. · NCT05607498 A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in
Phase 1 · Affiliated Hospital of Hebei University · Shanghai Henlius Biotech · NCT07477587 Efficacy and Safety of Xiangjurupining Capsule for Hyperplasia of Mammary Glands
Phase 3 · Guang 'anmen Hospital Baoding Hospital · Tasly Pharmaceutical Group Co., Ltd · NCT06685978

Look up another city

Look up another condition